Regeneron Pharmaceuticals has been making waves in the investment community with several announcements. Notably, the biotech firm demonstrated a series of successful late-stage trials and displayed steady growth in its equity holding by various firms. A key milestone was Libtayo's approval, potentially reshaping Regeneron's global oncology trajectory. DDD Partners LLC, Washington Trust Advisors Inc., and Ethic Inc. increased their holdings on Regeneron. However, ARK Investment Management LLC and Cullen Frost Bankers Inc. reduced their shares. Q3 earnings forecasts indicate potential decline, with an assessed value after recent modest share price gains. FDA extended its review on two submissions by the firm. It has been down after the FDA approved Libtayo as adjuvant immunotherapy for high-risk CSCC. Amidst fluctuations in the stock, analysis suggest that potential catalysts could drive the stock price higher and it continues to receive buy ratings. Meanwhile, the firm is keen on the approval of Odronextamab and eagerly anticipates a probable surge in Dupixent profits to counteract Eylea Sales Decline.
Regeneron Pharmaceuticals REGN News Analytics from Wed, 11 Jun 2025 07:00:00 GMT to Sat, 25 Oct 2025 14:16:52 GMT -
Rating 6
- Innovation 8
- Information 7
- Rumor -3
